How about Anke Biotechnology Enterprise

Anhui Anke Biotechnology (Group) Co., Ltd., the full name of Anhui Anke Biotechnology (Group) Co., Ltd., was established in It is a private joint-stock enterprise established in 1994 with the approval of the Anhui Provincial People's Government. It is a key high-tech enterprise in the National Torch Program and an industrialization base for the results of the National "863" Program. It has a provincial technology center and a postdoctoral research station. The company is one of the biopharmaceutical high-tech enterprises with the largest scale, the best efficiency and the strongest technical reserves in my country. [1]

Anke Biotechnology, the core enterprise of the group company, has always focused on the research and development of biotech drugs such as cell engineering products and genetic engineering products and the construction of core technical capabilities. It has successively undertaken more than 10 national "863" plan, national science and technology research projects, national key torch plans and provincial science and technology projects, and independently developed nearly 10 national-level new drugs. He has won the third prize of the National Science and Technology Progress Award once, the first prize of the Anhui Province Science and Technology Progress Award three times, the second prize of the Anhui Province Science and Technology Progress Award once, the Provincial Government Outstanding Contribution Award twice, and the Anhui Province Major Science and Technology Achievement Award once. [1]

In recent years, Anke Biotechnology has used tool enzymes commonly used in gene cloning technology for pharmaceuticals, commonly used plasmid vectors and phage vectors for gene cloning technology pharmaceuticals, preparation of target genes for genetic engineering drugs, and the relationship between target genes and cloning vectors. In vitro recombination, the introduction of recombinant cloning vectors into recipient cells, the screening, identification and analysis of target recombinant clones, and the expression of target genes in host cells have all formed their own comparative advantages. The leading products are recombinant human interferon α2b "Andafen" series preparations, recombinant human growth hormone "Ansumeng", and anti-sperm antibody detection (MAR method) kit "Ansibao", all of which are independently developed by Anke and are sold nationwide and exported. More than ten countries and regions. Among them, "Andafen" is my country's first domestically produced interferon α2b product, and "Ansibao", a result of the national "863" program, is the first commercialized MAR anti-sperm antibody detection reagent in the world. Currently, there are a number of projects under development such as the national scientific and technological research project "PEG Trichosanthes Trichosanthes Protein", the first-class new drug "Recombinant Human Albumin Fusion Interferon", and "PEG-Recombinant Human Growth Hormone". [1]

Member company Anhui Anke Yuliangqing Pharmaceutical Co., Ltd. was established by Anke Biotech by reorganizing the "Century-old Chinese Time-honored" traditional Chinese medicine enterprise "Yu Liangqing". It produces more than 30 varieties of traditional Chinese medicine in seven dosage forms, including rubber ointments, mixtures, granules, hard capsules, tinctures, ointments, and plasters. [1]

Member company Anhui Anke Hengyi Pharmaceutical Co., Ltd. is a company specializing in the production of pharmaceutical preparations. The main dosage forms include tablets, capsules, granules, syrups, ointments, powders, 7 dosage forms including oral solution. The main varieties include: cefaclor dispersible tablets, benoxate dispersible tablets, azithromycin powder, amoxicillin granules, cephalosporin capsules, granules, cefradine capsules, ammonia capsules and other 57 varieties. [1]

Currently, Anke Biotechnology is actively preparing to build the "Anhui Biotechnology and New Medicine Innovation and Entrepreneurship Incubation Center". This center will be constructed and operated entirely in a "market-oriented" model from fund raising to management. . The completed incubation center will provide Anhui Province with a new public technology platform for biotechnology and new medicine research, and cultivate a group of biotechnology and new medicine research and industries with strong independent innovation capabilities through the center's incubation function. chemical enterprise. [1]

/link?url=XjxlMl1eIH8_8isPkj_S0xJVKex5oCDw3dEk1AyIuV9ccWllh8e0HqRNlPRR9LjvBxyMDyststgH5w5wbOg-Bq